Study analysis · Circulation · 2024
This cholesterol pill lowers LDL by 30 points—but does NOTHING to stop your aorta from growing.
Taking a daily statin pill for 3 years cuts bad cholesterol but doesn't slow down the aorta's growth in people with a common heart defect.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
In simple terms
This study is like a fair test where half the kids got a new vitamin and half got a sugar pill, and then doctors measured their hearts with super-accurate scans. They found the vitamin didn't make their aorta grow slower or their valve calcify less. So we can say this vitamin didn't help in this group — but we don't know if it might help other kids with different hearts.
What’s the bottom line?
Some people are born with a heart valve that has two flaps instead of three. This can make their aorta (the big blood vessel from the heart) slowly grow bigger over time. Doctors thought giving a cholesterol-lowering pill might help stop that.
How strong is this study?
This study was super well-designed because nobody knew who got the real medicine or the fake one, and the scans were done by experts who didn't know who got what. That means the results are trustworthy. If they hadn't done it this way, we couldn't be sure if the results were because of the medicine or just because of other things like diet or luck.
75 / 100
- COI disclosure+40/40
- Data availability+35/35
- Code availabilitycode not shared
92 / 100
- Randomization+20/20
- Blinding+15/15
- Control group+15/15
- Sample size (n=220)+13.3/20
- Follow-up+10/10
100 / 100
100 / 100
- P-values+15/15
- Effect size+20/20
- Confidence intervals+15/15
- Pre-registration+15/15
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 590 / 100
Probability of being correct
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
This design can establish causation. This study can establish causation because it is a randomized controlled trial with double blinding and a control group, which minimizes confounding. However, the lack of statistically significant results means it can only conclude that atorvastatin did not cause a reduction in aortic dilation or valve calcification in this population under these conditions.
No Conflicts
No conflicts of interest identified
No conflicts of interest were disclosed, and while the study was funded by public sources, there is no evidence of industry influence on study design, analysis, or publication.
Funders
Independent Analysis Safeguards
- Centralized core laboratory performed CT analysis blinded to treatment allocation
- Double-blind randomized design
- Randomization handled by pharmacy department with sealed envelopes
The study was funded by public Spanish research institutions with no industry involvement. All analyses were conducted by a blinded core laboratory, and the trial was registered prospectively with full transparency. No author affiliations or relationships with pharmaceutical companies were disclosed, and there is no indication of industry funding or influence.
Key takeaways
- 01
After 3 years, the pill lowered cholesterol by 30 points, but the aorta grew the same amount in both the pill group and the placebo group — about 0.7 mm per year.
- 02
Even though the pill worked to lower cholesterol, it didn’t slow down the aorta’s growth or prevent new calcium buildup on the valve — meaning the pill didn’t help with the main problem.
Surprising findings
- Atorvastatin didn’t slow aortic dilation despite cutting LDL by 30 mg/dL.Statins are known to stabilize plaques and reduce aneurysm growth in abdominal aortas—so it’s shocking they had zero effect on the ascending aorta in this genetic condition.
- The annual aortic dilation rate was only 0.23 mm/year—far lower than prior estimates.Most prior studies used echocardiography, which overestimated growth. This study used gold-standard CT scans and found progression was nearly half what was believed.
Practical takeaways
If you have bicuspid aortic valve and no calcification, ask your doctor about CT monitoring instead of echo—this study shows CT gives more accurate progression rates.
This study only applies to people with mild or no valve dysfunction and no calcification. It doesn’t apply to those with severe stenosis or advanced disease.
high confidenceDon’t assume statins will protect your aorta if you have BAV—this study shows they don’t slow dilation, even when they lower cholesterol.
Statins may still be prescribed for other reasons like high LDL or family history of heart disease—this doesn’t mean stop them, just don’t expect them to fix your aorta.
high confidenceWhy this study matters
Statins Work—But Not Here
Atorvastatin lowered LDL cholesterol by a median of 30 mg/dL (P<0.001), proving it worked as intended. But despite this, the aorta grew just as much in the pill group (0.65 mm) as in the placebo group (0.74 mm) over 3 years (P=0.613).
People assume lowering cholesterol automatically protects the heart and arteries—but this study shows that’s not always true, especially for genetic conditions like bicuspid aortic valve.
The Aorta Grows Slower Than We Thought
The study found the annual aortic dilation rate was only 0.23 mm/year—much lower than prior estimates of 0.42 mm/year from echocardiography. This suggests past studies may have overestimated progression.
If the aorta grows slower than we thought, it changes how we monitor patients and when we consider surgery—potentially reducing unnecessary anxiety and interventions.
The Calcium Paradox
While statins didn’t reduce overall valve calcification (P=0.167), patients with zero baseline calcium who took atorvastatin were 95% likely to stay calcium-free vs. 80% in placebo—a trend (P=0.055) that hints at early prevention potential.
This suggests statins might help prevent calcium buildup if given early—before calcification starts—opening a door for future targeted trials.
Want the whole report?
Detailed mode opens the full scientific breakdown — every score component, the methodology, conflicts of interest, the evidence analysis behind each claim, and the raw study data.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
Some people are born with a heart valve that has two flaps instead of three. This can make their aorta (the big blood vessel from the heart) slowly grow bigger over time. Doctors thought giving a cholesterol-lowering pill might help stop that.
Research results
After 3 years, the pill lowered cholesterol by 30 points, but the aorta grew the same amount in both the pill group and the placebo group — about 0.7 mm per year.
What this means - more context
Even though the pill worked to lower cholesterol, it didn’t slow down the aorta’s growth or prevent new calcium buildup on the valve — meaning the pill didn’t help with the main problem.
Does atorvastatin reduce ascending aorta dilation or aortic valve calcification in adults with bicuspid aortic valve and no severe dysfunction?
In a 3-year randomized trial of 220 adults with bicuspid aortic valve and no severe valvular dysfunction or calcification, daily 20 mg atorvastatin significantly lowered LDL cholesterol by a median of 30 mg/dL but did not reduce progression of ascending aorta dilation or aortic valve calcification compared to placebo.
Methods Used
Double-blind, randomized, placebo-controlled trial with 220 adults (mean age 46) with bicuspid aortic valve, no severe dysfunction, and ascending aorta diameter ≤50 mm. Primary and secondary outcomes were measured via CT and echocardiography at baseline and 3 years; core-lab analysis blinded to treatment group.
Main Finding
Atorvastatin reduced LDL cholesterol by a median of 30 mg/dL (P<0.001) but did not significantly reduce ascending aorta dilation (0.65 mm vs. 0.74 mm, P=0.613) or aortic valve calcification progression (P=0.167) over 3 years.
Confidence Level
High — robust methodology: double-blind, randomized, placebo-controlled, pre-registered, CT-based outcomes with core-lab analysis, adequate power, low dropout rate, and consistent reporting of effect sizes and confidence intervals.
Study Flags
Red Flags
- •Subgroup analyses were non-prespecified and not statistically significant
- •3-year duration may be too short to detect long-term effects
- •Low annual aortic dilation rate (0.23 mm/year) may have reduced statistical power
No biological mechanisms were identified in this study. This may be an epidemiological, observational, or survey-based study that reports associations rather than proposing causal biological pathways.
Surprising Findings
Atorvastatin didn’t slow aortic dilation despite cutting LDL by 30 mg/dL.
Statins are known to stabilize plaques and reduce aneurysm growth in abdominal aortas—so it’s shocking they had zero effect on the ascending aorta in this genetic condition.
Practical Takeaways
If you have bicuspid aortic valve and no calcification, ask your doctor about CT monitoring instead of echo—this study shows CT gives more accurate progression rates.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 590 / 100
Probability of being correct
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
Human RCT
Subject
High probability
on the GRADE evidence scale
This study is like a fair test where half the kids got a new vitamin and half got a sugar pill, and then doctors measured their hearts with super-accurate scans. They found the vitamin didn't make their aorta grow slower or their valve calcify less. So we can say this vitamin didn't help in this group — but we don't know if it might help other kids with different hearts.
The study has a COI section but no disclosure was found. A small penalty has been applied.
Strengths
- Randomized and double-blinded design with placebo control
- Use of CT imaging (gold standard) for precise aortic and valve measurements
- Centralized core laboratory analysis blinded to treatment allocation
Weaknesses
- Sample size may have been underpowered to detect small but clinically meaningful effects
- Relatively low dose of atorvastatin (20 mg) may not reflect optimal therapeutic effect
- Non-prespecified subgroup analyses conducted without adjustment for multiple comparisons
Methodology
Evidence Keywords
Statistical Reporting
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
Some people are born with a heart valve that has two flaps instead of three. This can make their aorta (the big blood vessel from the heart) slowly grow bigger over time. Doctors thought giving a cholesterol-lowering pill might help stop that.
Research results
After 3 years, the pill lowered cholesterol by 30 points, but the aorta grew the same amount in both the pill group and the placebo group — about 0.7 mm per year.
What this means - more context
Even though the pill worked to lower cholesterol, it didn’t slow down the aorta’s growth or prevent new calcium buildup on the valve — meaning the pill didn’t help with the main problem.
Does atorvastatin reduce ascending aorta dilation or aortic valve calcification in adults with bicuspid aortic valve and no severe dysfunction?
In a 3-year randomized trial of 220 adults with bicuspid aortic valve and no severe valvular dysfunction or calcification, daily 20 mg atorvastatin significantly lowered LDL cholesterol by a median of 30 mg/dL but did not reduce progression of ascending aorta dilation or aortic valve calcification compared to placebo.
Methods Used
Double-blind, randomized, placebo-controlled trial with 220 adults (mean age 46) with bicuspid aortic valve, no severe dysfunction, and ascending aorta diameter ≤50 mm. Primary and secondary outcomes were measured via CT and echocardiography at baseline and 3 years; core-lab analysis blinded to treatment group.
Main Finding
Atorvastatin reduced LDL cholesterol by a median of 30 mg/dL (P<0.001) but did not significantly reduce ascending aorta dilation (0.65 mm vs. 0.74 mm, P=0.613) or aortic valve calcification progression (P=0.167) over 3 years.
Confidence Level
High — robust methodology: double-blind, randomized, placebo-controlled, pre-registered, CT-based outcomes with core-lab analysis, adequate power, low dropout rate, and consistent reporting of effect sizes and confidence intervals.
Study Flags
Red Flags
- •Subgroup analyses were non-prespecified and not statistically significant
- •3-year duration may be too short to detect long-term effects
- •Low annual aortic dilation rate (0.23 mm/year) may have reduced statistical power
No biological mechanisms were identified in this study. This may be an epidemiological, observational, or survey-based study that reports associations rather than proposing causal biological pathways.
Surprising Findings
Atorvastatin didn’t slow aortic dilation despite cutting LDL by 30 mg/dL.
Statins are known to stabilize plaques and reduce aneurysm growth in abdominal aortas—so it’s shocking they had zero effect on the ascending aorta in this genetic condition.
Practical Takeaways
If you have bicuspid aortic valve and no calcification, ask your doctor about CT monitoring instead of echo—this study shows CT gives more accurate progression rates.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 590 / 100
Probability of being correct
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
Human RCT
Subject
High probability
on the GRADE evidence scale
This study is like a fair test where half the kids got a new vitamin and half got a sugar pill, and then doctors measured their hearts with super-accurate scans. They found the vitamin didn't make their aorta grow slower or their valve calcify less. So we can say this vitamin didn't help in this group — but we don't know if it might help other kids with different hearts.
The study has a COI section but no disclosure was found. A small penalty has been applied.
Strengths
- Randomized and double-blinded design with placebo control
- Use of CT imaging (gold standard) for precise aortic and valve measurements
- Centralized core laboratory analysis blinded to treatment allocation
Weaknesses
- Sample size may have been underpowered to detect small but clinically meaningful effects
- Relatively low dose of atorvastatin (20 mg) may not reflect optimal therapeutic effect
- Non-prespecified subgroup analyses conducted without adjustment for multiple comparisons
Methodology
Evidence Keywords
Statistical Reporting
Scoring
How strong is this study?
This study was super well-designed because nobody knew who got the real medicine or the fake one, and the scans were done by experts who didn't know who got what. That means the results are trustworthy. If they hadn't done it this way, we couldn't be sure if the results were because of the medicine or just because of other things like diet or luck.
75 / 100
- COI disclosure+40/40
- Data availability+35/35
- Code availabilitycode not shared
92 / 100
- Randomization+20/20
- Blinding+15/15
- Control group+15/15
- Sample size (n=220)+13.3/20
- Follow-up+10/10
100 / 100
100 / 100
- P-values+15/15
- Effect size+20/20
- Confidence intervals+15/15
- Pre-registration+15/15
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 590 / 100
Probability of being correct
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
This design can establish causation. This study can establish causation because it is a randomized controlled trial with double blinding and a control group, which minimizes confounding. However, the lack of statistically significant results means it can only conclude that atorvastatin did not cause a reduction in aortic dilation or valve calcification in this population under these conditions.
No Conflicts
No conflicts of interest identified
No conflicts of interest were disclosed, and while the study was funded by public sources, there is no evidence of industry influence on study design, analysis, or publication.
Funders
Independent Analysis Safeguards
- Centralized core laboratory performed CT analysis blinded to treatment allocation
- Double-blind randomized design
- Randomization handled by pharmacy department with sealed envelopes
The study was funded by public Spanish research institutions with no industry involvement. All analyses were conducted by a blinded core laboratory, and the trial was registered prospectively with full transparency. No author affiliations or relationships with pharmaceutical companies were disclosed, and there is no indication of industry funding or influence.
Standing
Who’s using this study?
The videos and claims on this site that lean on this study, and the researchers who wrote it.
1 video from Dr Brad Stanfield cite this study, drawing 1 claim from it.
- Strong evidence
At least some randomized or controlled trials support this claim.
Evidence
Authored by
21 researchersIf this is your work, this is how we attribute it on Fit Body Science. Arturo Evangelista is listed as the lead author.